AANEM News Express

AANEM News Express

Myasthenia Gravis Treated with Autologous Hematopoietic Stem Cell Transplantation

12/14/2016
 
Bryant A, Atkins H, Pringle CE, et al. Myasthenia Gravis Treated with Autologous Hematopoietic Stem Cell Transplantation. JAMA Neurol 2016;73:652-658.

Submitted by Niranjan N. Singh, MD, News Science Editorial Board
The authors report a series of seven patients (two of whom were seronegative) with severe myasthenia gravis treated with autologous hematopoietic stem cell transplantation. Patients were refractory to treatment with multiple treatment modalities including pyridostigmine, corticosteroids, azathioprine, mycophenolate mofetil, cyclosporine, intravenous immunoglobulin, plasma exchange, and thymectomy. The protocol included graft mobilization and purification, treatment with intensive conditioning chemotherapy, and graft reinfusion. All patients achieved complete stable remission with no residual myasthenia gravis symptoms or requirement for disease-modifying therapy.


Comment: Refractory myasthenia gravis accounts for 10% of disease. Hematopoietic stem cell transplantation offers a potential treatment option for patients in this group. It should be emphasized that this study is a retrospective case series, and that stem cell transplantation has not been studied in a prospective fashion in patients with myasthenia gravis.


About the AANEM News Science Editorial Board

The board helps to highlight significant, timely science news items for AANEM members. It reviews articles in journals and websites, identifies newsworthy items in the field, and writes article summaries.


View Related News Stories:

  Practice


Recent AANEM News

Exciting Changes Coming to ABEM’s Maintenance of Certification Program

Carolina Barnett-Tapia, MD, Named Inaugural Young Lectureship Award Winner

Science News: Nusinersen in Type 1 Spinal Muscular Atrophy: Twelve-Month Real-World Data

Science News: Reduction of Skin Innervation is Associated with a Severe Fibromyalgia Phenotype

The American Neuromuscular Foundation is Seeking a Public Board Member





Advertisement

ABEM

Advertisement

TPP

Advertisement

Devon products